The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of 8.5%, reaching US$ ...

The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of ...

Abbott Laboratories’ ABT growth in the fourth quarter of 2024 can be attributed to strong improvement in global Core ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Continuous Glucose Monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

Stifel raised the firm’s price target on Abbott (ABT) to $135 from $130 and keeps a Buy rating on the shares. The firm views Abbott’s Q4 ...